Which biomarker tests (PSA) are recommended for my Prostate Cancer, and how will the results guide my diagnosis and...

PSA and Biomarker Testing for Prostate Cancer

Great question! Let me walk you through how PSA testing works and what other biomarker tests your care team might recommend.

---

PSA (Prostate-Specific Antigen) — The Standard Test

What it measures: PSA is a protein made by your prostate gland. According to the NCCN Guidelines for Patients: Early-Stage Prostate Cancer, PSA is measured in nanograms per milliliter (ng/mL) of blood. All prostate cells—both normal and cancer cells—produce PSA, so an unusually high amount in your bloodstream may signal prostate cancer.

Important context: A high PSA doesn't automatically mean you have cancer. Age, urinary tract infections, an enlarged prostate, or other conditions can also raise PSA levels. That's why PSA testing is paired with other tests like a digital rectal exam or imaging.

How it guides treatment:

• Rising PSA after treatment may indicate that your treatment is losing effectiveness
• PSA levels help determine your risk group (low, intermediate, or high-risk), which directly influences whether you need active treatment or can safely use active surveillance (careful monitoring without immediate treatment)

---

Beyond PSA: Advanced Biomarker Tests

According to the NCCN Guidelines, if your PSA is elevated, your doctor may recommend additional blood or urine biomarker tests to help decide if you need a biopsy. These include:

Blood Tests:

• 4Kscore — measures PSA and other proteins to predict cancer risk
• PHI (Prostate Health Index) — combines PSA measurements to improve accuracy
• IsoPSA — a PSA variant that may better distinguish cancer from benign conditions

Urine Tests:

• PCA3 — detects cancer-related RNA in urine
• SelectMDx — genetic markers in urine cells
• ExoDx — analyzes genetic material in urine
• MPS (Michigan Prostate Score) — combines multiple urine markers

---

Molecular Biomarker Tests (Tumor Profiling)

According to the NCCN Guidelines, if you're diagnosed with prostate cancer, your doctor may recommend molecular biomarker testing on your biopsy tissue. These tests look at the genetic makeup of your cancer and can help identify:

• Lower-risk cancers that may not need aggressive treatment right away
• Specific mutations that respond to targeted therapies
• Prognosis (how your cancer is likely to progress)

Common molecular tests include:

• Decipher — predicts risk of cancer spread
• Genomic Prostate Score (GPS) — assesses aggressiveness
• Prolaris — measures cancer cell growth rate

These tests can help spare you from unnecessary aggressive treatment and its side effects.

---

Genetic Testing for Inherited Risk

According to expert guidance on prostate cancer, genetic testing can identify mutations like:

• BRCA1/BRCA2 — inherited mutations that increase cancer risk and may respond to PARP inhibitors
• ATM mutations — affect DNA repair and treatment response

If you have a family history of cancer, ask your doctor about germline testing (testing your normal cells for inherited mutations).

---

Advanced Tests for Metastatic (Spread) Cancer

If your cancer has spread, additional tests may include:

• Circulating Tumor DNA (ctDNA) — a blood test that detects cancer DNA floating in your bloodstream; useful for monitoring disease progression
• PSMA PET scan — uses a radioactive tracer to find prostate cancer cells throughout your body
• Microsatellite Instability (MSI) — predicts response to immunotherapy
• Mismatch Repair Deficiency — identifies DNA repair problems that may respond to specific drugs

---

How Results Guide Your Treatment Plan

STEP 1 — RISK ASSESSMENT: Your PSA level, Gleason score (how aggressive your cancer looks under a microscope), and imaging results determine your risk group:

• Very low/low-risk → Active surveillance (monitoring) often recommended
• Intermediate-risk → May use surgery, radiation, or hormone therapy
• High-risk → Usually requires combination treatment (surgery + radiation, or radiation + hormone therapy)

STEP 2 — MOLECULAR INSIGHTS: Biomarker tests reveal:

• Whether your cancer is hormone-sensitive (responds to androgen deprivation therapy)
• Whether you have mutations that respond to targeted drugs (like PARP inhibitors for BRCA mutations)
• Your likelihood of cancer spreading

STEP 3 — TREATMENT SELECTION: Results help your oncologist choose between:

• Active surveillance (if low-risk)
• Surgery (radical prostatectomy)
• Radiation therapy
• Hormone therapy (androgen deprivation)
• Chemotherapy (for advanced disease)
• Targeted therapies (based on specific mutations)
• Clinical trials (if standard options aren't working)

---

Questions to Ask Your Oncologist

1. What is my PSA level, and what does it mean for my risk group?
2. Do you recommend molecular biomarker testing on my biopsy? Which test and why?
3. Based on my results, what treatment options are most appropriate for me?
4. Do I have any genetic mutations (like BRCA or ATM) that would change my treatment?
5. If I choose active surveillance, how often will my PSA be monitored?
6. Are there clinical trials available based on my specific biomarkers?

---

Key Takeaway

According to the NCCN Guidelines, PSA testing is just the starting point. Molecular biomarker tests on your actual tumor tissue provide much more personalized information about your cancer's behavior and which treatments are most likely to work for YOU. This helps avoid unnecessary aggressive treatment while ensuring you get the right therapy.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.